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Immune responses can be enhanced or damp-
ened by differential manipulation of Foxp3-
expressing CD25+CD4+ natural regulatory
T (Treg) cells versus other naive or activated
T cells. By searching for a molecule capable of
distinguishing these populations, we here
found that natural Treg cells constitutively
expressed high amounts of folate receptor 4
(FR4). The expression of FR4 and CD25 also
separated antigen-stimulated CD4+ non-Treg
cells into the FR4hiCD25 and FR4loCD25+ pop-
ulations, which were different in proliferation
and cytokine secretion upon restimulation.
These distinctions showed that antigenic
stimulation activated and expanded antigen-
specific natural Treg cells as well as effector
and memory T cells. Accordingly, FR4hi
CD25+CD4+ T cells enriched from alloantigen-
stimulated T cells suppressed graft rejection.
Administration of FR4 monoclonal antibody
specifically reduced Treg cells, provoking
effective tumor immunity in tumor-bearing
animals, whereas similar treatment of normal
young mice elicited autoimmune disease.
Thus, specific manipulation of FR4hiCD25+
CD4+ Treg cells helps control ongoing immune
responses.
INTRODUCTION
The immune systemendogenously produces aCD4+ T cell
subpopulation that is highly specialized to suppress aber-
rant or excessive immune responses (Sakaguchi, 2000). A
cardinal feature of such CD4+ naturally occurring regula-
tory T (Treg) cells is that the majority of them constitutively
express CD25 (the interleukin-2 receptor a chain) and the
transcription factor Foxp3 that specifically controls their
development and function (Fontenot and Rudensky,2005; Malek and Bayer, 2004; Sakaguchi, 2004). The
Foxp3-expressing CD25+CD4+ Treg cells are apparently
reactivewith abroad spectrumof self and nonself antigens
and able to expand upon in vivo and in vitro strong anti-
genic stimulation (Hsieh et al., 2004; Jordan et al., 2001,
Nishimura et al., 2004). They are engaged in suppressing
the development of immunological diseases such as auto-
immune disease and allergy. They can also be exploited to
establish transplantation tolerance through their antigen-
specific expansion and to provoke effective immunity
against autologous tumor cells or enhance immune
responses to invading microbes through their reduction
in number or attenuation of their suppressive activity.
An important feature of natural Treg cells is that they are
phenotypically in an activated or antigen-primed state
(Sakaguchi, 2004). This makes it difficult to phenotypically
distinguish natural Treg cells from other activated effector
or memory T cells. To further determine the role of natural
Treg cells in controlling immune responses, it is therefore
necessary to identify a cell-surface molecule that can
specifically distinguish them fromother Tcells, in particular
from activated effector or memory T cells. There are
several cell-surface molecules that are predominantly
expressed in natural Treg cells. CD25, for example, is
indispensable for the maintenance of natural Treg cells
as an essential component of the high-affinity interleukin-
2 (IL-2) receptor because they are highly dependent on
exogenous IL-2 for their peripheral survival (D’Cruz and
Klein, 2005; Fontenot et al., 2005; Setoguchi et al., 2005).
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)
and glucocorticoid-induced tumor necrosis factor recep-
tor family-related gene or protein (GITR) are expressed
constitutively and at high amounts in natural Treg cells
and involved in Treg cell-mediated suppression (McHugh
et al., 2002; Read et al., 2000; Salomon et al., 2000; Shi-
mizu et al., 2002; Takahashi et al., 2000). Although these
molecules are useful for operationally differentiating natu-
ral Treg cells from other T cells in immunologically naive
animals, they are unable to fully distinguish natural Treg
cells from activated T cells because every T cell expresses
them upon activation (Ono et al., 2006).
We show in this report that natural Treg cells consti-
tutively express high amounts of the folate receptorImmunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 145
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Regulatory T Cells Expressing the Folate ReceptorFigure 1. High Expression of FR4 in Natural CD25+CD4+ Treg Cells
(A) CD25+CD4+, CD25CD4+, and CD8+ T cells before and after stimulation for 3 and 6 days with 0.5 mg/ml of anti-CD3 (2C11), 50 U/ml IL-2, and
irradiated spleen cells were stained with TH6 (lines) or rat IgG2b (shaded).
(B) Immunoblotting of normal spleen T cells with 12A5 mAb after immunoprecipitation with TH6, 12A5, or normal rat IgG. An aliquot of the immuno-
precipitate with TH6 was treated with N-glycosidase before blotting (Shimizu et al., 2002). Molecular size is shown on the left side.
(C) Cos-7 cells transfected with the mouse FR4 gene (solid line) or nontransfected (shaded) were stained with TH6 and 12A5.
(D) Specific fragments of cDNA for the FR1, FR2, FR4, and HPRT genes were amplified by RT-PCR with cDNA of placenta, CD19+, CD8+, and CD4+
spleen cells.
(E) CD25CD4+ cells were infected with the bi-cistronic retroviral vector MIGR1 coding for GFP and Foxp3 or GFP alone (Hori et al., 2003), were
stained with TH6. Shown are representative of three independent experiments.4 (FR4), a subtype of the receptor for the vitamin folic acid,
and this high expression of FR4 can distinguish them from
other naive or activated T cells. In addition, combinations
of high or low expression of FR4 and CD25 can distinguish
four functionally different CD4+ T cell subpopulations; i.e.,
natural Treg cells, effector T cells, memory-like T cells, and
naive T cells. With FR4 as a specific marker for natural
Treg cells, we address the questions of whether natural
Treg cells become antigen activated and clonally expand
in physiological and pathological immune responses, how
immune responses are controlled by the dynamic balance
between Treg cells and effector or memory T cells, and
how ongoing immune responses can be altered for the
benefit of the host by differential manipulation of antigen-
activated Treg cells and effector or memory T cells.146 Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc.RESULTS
High Expression of FR4 in CD25+CD4+ Treg Cells
By immunizing rats with activated CD25+CD4+ T cell
suspensions from normal mice, we obtained two rat
monoclonal antibodies (mAbs), designated TH6 and
12A5 of rat IgG2b and IgG1 isotype, respectively. Both
mAbs stained CD25+CD4+ T cells at a higher level than
other CD4+ or CD8+ T cells even after activation
(Figure 1A) and recognized a highly glycosylated protein
of 35 kDa in normal spleen cells by immunoprecipitation
(Figure 1B). Mass-Fingerprint analysis of the amino acid
composition of the precipitate revealed the molecule as
mouse FR4, also called folate receptor d and folate bind-
ing protein 3 (Elnakat and Ratnam, 2004; Spiegelstein
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specific staining of monkey Cos-7 cells transfected with
the Folr4 gene that encodes mouse FR4 (Figure 1C).
FR4 is known to be expressed exclusively in lymphoid
tissue but has been little characterized in contrast to the
well-studied FR1 and FR2, which are mainly expressed
in epithelial cells and hematopoietic cells other than
lymphocytes, respectively (Elnakat and Ratnam, 2004;
Spiegelstein et al., 2000). Among three known subtypes
of mouse FRs, splenic lymphocytes, T cells (especially),
and mature thymocytes expressed mRNA and protein
for FR4 but not for FR1 or FR2 (Figure 1D; Figure S1 in
the Supplemental Data available online). Human Treg cells
also expressed a homolog of mouse FR4 (Figure S2). Ret-
roviral transduction of Foxp3, which can functionally and
phenotypically convert normal T cells to natural Treg-like
cells (Fontenot et al., 2003; Hori et al., 2003), revealed
that the FR4 expression was proportional to that of
Foxp3 in Foxp3-transduced CD25CD4+ T cells, suggest-
ing that Foxp3 directly or indirectly controls the expression
of FR4 in natural Treg cells (Figure 1E).
Separation of Treg Cells from Activated T Cells
after In Vitro Stimulation
Staining of CD4+ T cells in normal naivemice for CD25 and
FR4 revealed two discrete populations (fractions a and
b in Figure 2A). Notably, stimulation of BALB/c CD4+ T
cells with allogeneic B6 spleen cells gave rise to three
populations well demarcated by high (hi), intermediate
(int), or low (lo) expression of FR4 and CD25; i.e., the
FR4hiCD25hi, FR4intCD25int-hi, and FR4loCD25 popula-
tions (fractions c, d, and e, respectively, in Figure 2A),
which constituted 5%, 35%, and 60%, respectively,
of CD4+ T cells. Allogeneic (B6) stimulation of BALB/c
CD8+ T cells generated FR4intCD25hi cells and
FR4loCD25 cells, which constituted 25% and 75%,
respectively, but not FR4hiCD25hi cells. When
CD25+CD4+ T cells prepared from normal Thy1.2-BALB/c
mice were mixed with CD25CD4+ T cells from
Thy1.1-BALB/c congenic mice and similarly stimulated
with B6 spleen cells, the majority of stimulated
Thy1.2+CD25+CD4+ T cells differentiated to FR4hiCD25hi
cells as a phenotypically discrete population (Figure 2B).
Foxp3-expressing CD4+ T cells, including CD25+ and
CD25 cells, were FR4hi before and after allogeneic stim-
ulation (Figure 2C; Figure S3). The FR4hiCD25hiCD4+ T
cells indeed expressed Foxp3 mRNA at equivalent
amounts as naive CD25+CD4+ T cells, whereas other pop-
ulations did not (Figure 2D). In addition, Foxp3+CD4+ T
cells induced in vitro from naive T cells by allogeneic stim-
ulation in the presence of high-dose transforming growth
factor-b (TGF-b) were also FR4hiCD25hi (Figure S4; Chen
et al., 2003). Thus, Foxp3-expressing CD4+cells, whether
they are naturally arising or induced from naive T cells, are
persistently FR4hi before and after antigenic stimulation.
Functionally, the FR4hiCD25hi population in alloantigen-
stimulated CD4+ T cells (fraction c in Figure 2A) were
hypoproliferative to in vitro restimulation (Figure 2E) and
suppressed the proliferation of CD25CD4+ T cells(Figure 2F), being similar to the CD25+CD4+ Treg cell
population in naivemice (fraction a in Figure 2A; Takahashi
et al., 1998; Thornton and Shevach, 1998). Importantly,
these antigen-stimulated FR4hiCD25hi cells were more
potent in in vitro suppression than FR4hiCD25hi cells
from naive mice and showed antigen specificity: B6-
stimulated BALB/c FR4hiCD25hiCD4+ T cells were more
potent in suppressing anti-B6 response than
CD25+CD4+ naive or C3H-stimulated FR4hiCD25hiCD4+
T cells (Figure 2F). Likewise, C3H-stimulated FR4hiCD25hi
BALB/c T cells were more potent than B6-stimulated or
their nonstimulated counterpart in suppressing anti-C3H
response. The alloantigen-stimulated FR4hiCD25hi cells
also strongly suppressed rejection of allogeneic skin graft
(Figures 2G and 2H): although BALB/c athymic nude mice
rejected B6 skin grafts within 30 days after transfer of
BALB/c naive T cells, cotransfer of in vitro B6-stimulated
FR4hiCD25hi cells and BALB/c naive T cells significantly
prolonged the graft survival to average 45 days, whereas
cotransfer of naive CD25+ cells was much less effective
in prolongation. When nude mice with prior transplanta-
tion of both B6 and C3H skins were transferred with the
mixture of BALB/c naive T cells and B6-stimulated
BALB/c FR4hiCD25hi T cells, the cell transfer led to signif-
icantly longer survival of B6 grafts than C3H grafts, while
cotransfer with C3H-stimulated BALB/c FR4hiCD25hi
T cells significantly prolonged the survival of C3H grafts
compared with B6 grafts (Figure 2H).
In contrast with FR4hiCD25hi T cells, which were
suppressive, antigen-stimulated FR4intCD25int-hiCD4+ T
cells (fraction d in Figure 2A) appeared to be antigen-
primed effector T cells because they showed earlier and
more vigorous proliferation to allostimulation compared
with FR4loCD25lo (fraction e) or naive CD25CD4+ T cells
(fraction b) (Figure 2E). In addition, transfer of these B6-
stimulated BALB/c FR4intCD25int-hiCD4+ T cells resulted
in significantly shorter survival of B6 skin grafts in BALB/
c nude mice compared with transfer of BALB/c naive T
cells (Figure 2G).
These results collectively indicate that antigen-stimu-
lated CD4+ T cells can be differentiated by the expression
of FR4 and CD25 into activated Treg cells, activated effec-
tor T cells, and naive T cells as FR4hiCD25hi, FR4intC-
D25int-hi, and FR4loCD25lo cells, respectively. In addition,
this demarcation reveals that antigen stimulation not
only activates and expands antigen-reactive effector
T cells but also confers antigen-specific suppressive
activity to the FR4hiCD25hi fraction. Thus, antigen-reactive
CD4+ T cells with opposite functions can be well sepa-
rated by expression levels of FR4.
In Vivo Distinction of Treg Cells from Effector
and Memory T Cells
We next examined whether Treg cells could be differen-
tiated from effector or memory T cells after in vivo anti-
gen stimulation. We immunized ovalbumin (OVA) in
complete Freund’s adjuvant (CFA) to DO11.10 transgenic
mice, which express a transgenic T cell receptor (TCR)
specific for an OVA peptide (Murphy et al., 1990), or toImmunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 147
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Regulatory T Cells Expressing the Folate ReceptorFigure 2. Antigen-Specific Suppression of Allogeneic Immune Responses by In Vitro Stimulated Treg Cells
(A) FR4 and CD25 expression of BALB/c CD4+ and CD8+ T cells before and after allogeneic stimulation with B6 irradiated splenocytes for 6 days.
Numbers indicate the percentages of gated cells.
(B) FR4 and CD25 expression by BALB/c Thy1.2+CD25+CD4+ T cells (black dots) and BALB/c Thy1.1+CD25CD4+ T cells (gray dots) mixed at 1:5
ratio and stimulated as in (A).
(C) FR4 and intracellular Foxp3 expression of BALB/c CD4+ T cells before and after B6 stimulation as in (A).148 Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc.
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which lack natural CD25+CD4+ Treg cells (Figure 3A;
Itoh et al., 1999). FR4hiCD25hiCD4+ T cells increased in
the regional lymph nodes of immunized DO11.10 mice,
in which the majority of Foxp3+ T cells were FR4hiCD25hi
as shown by intracellular staining of Foxp3, whereas
Rag2/ DO11.10 mice failed to develop FR4hiCD25hi
or Foxp3+CD4+ T cells (Figure 3A). Intracellular staining
of Bcl-2, an antiapoptotic protein, showed that the
FR4hiCD25hi fraction in naive mice included apoptosis-
prone Bcl-2lo cells at a higher ratio than other T cell
fractions and that Bcl-2lo cells increased among
FR4hiCD25hiCD4+ T cells and Foxp3+ cells after antigen
stimulation (Figure 3B; Figure S5). Similarly, CTLA-4hi
cells increased among FR4hiCD25hi cells after antigen
stimulation (Figure S5). The results indicate that at least
some antigen-stimulated Treg cells, which express
CD44, CD69, CD103, IL-7Ra (CD127), and CTLA-4 at
higher amounts than unstimulated Treg cells (Figure S5),
become Bcl-2lo and may die by apoptosis.
Functionally, FR4hiCD25hi cells in OVA-CFA-immunized
BALB/c mice 1 week or 3 months after immunization
(Figures 3D and 3E, respectively) did not proliferate nor
produce IL-2 or interferon-g (IFN-g) upon in vitro OVA re-
stimulation. They suppressed the proliferation of Rag2/
DO11.10 T cells in a dose-dependent fashion and more
potently than FR4hiCD25hi cells from BALB/c mice treated
with CFA alone, whereas the suppressive activities of
FR4hiCD25hi cells from the OVA-immunized or -nonimmu-
nized BALB/c mice were equivalent when polyclonally
stimulated with CD3 mAb (Figure 3F).
In addition to the increase in the number of FR4hiCD25hi
cells after OVA-CFA immunization, the immunization re-
sulted in a marked and slight increase in the number of
FR4hiCD25CD4+ T cells and FR4loCD25+CD4+ T cells,
respectively, in the regional lymph nodes of both RAG2-
intact and -deficient DO11.10 mice (Figure 3A). FR4hi
CD25 and FR4loCD25+CD4+ T cells similarly increased
in the regional lymph nodes of normal BALB/cmice immu-
nized with OVA-CFA, although less conspicuous than
DO11.10 mice (Figure 3C). Interestingly, upon in vitro
OVA restimulation 1 week after OVA immunization,
BALB/c FR4hiCD25CD4+ cells vigorously proliferated
and produced IL-2, but scarcely produced IFN-g, whereas
FR4loCD25+CD4+ cells proliferated and produced IL-2 to
a lesser degree but almost solely produced a large amount
of IFN-g (Figure 3D). Even 3 months after immunization,
lymph node FR4hiCD25 cells proliferated and produced
IL-2 but not IFN-g in response to in vitro OVA restimula-tion, whereas other fractions failed to proliferate or
produce cytokines (Figure 3E). Furthermore, T cells
secreting IL-17 in chronic inflammation, for example, in
spontaneous T cell-mediated autoimmune arthritis in
SKG mice, were confined to FR4loCD25+CD4+ T cells
in lymph nodes (Figure 3G; Hirota et al. 2007). Phenotyp-
ically, both FR4hiCD25 and FR4loCD25+ cells in naive
DO11.10 and normal BALB/c mice expressed various
activation markers (e.g., CD69, CD44, IL-2Rb [CD122],
GITR, and IL-7Ra) differently (Figures S5 and S6).
These functional and phenotypic characteristics of the
FR4-CD25 subpopulations indicate that, in addition to
FR4hiCD25hi cells as natural Treg cells, activated non-
Treg CD4+ cells can be differentiated into two pheno-
typically and functionally discrete populations; i.e.,
FR4loCD25+ effector (and presumably effector memory)
T cells and FR4hiCD25 cells including memory (espe-
cially central memory) T cells (Lanzavecchia and Sallusto,
2005; Reinhardt et al., 2001). Furthermore, this distinction
of Treg cells from activated non-Treg cells reveals that not
only in vitro allogeneic stimulation (Figure 2) but also in
vivo stimulation with protein antigen enhances antigen-
specific suppressive activity of the Foxp3+FR4hiCD25hi
Treg cell population.
In Vivo Antigen-Specific Clonal Expansion
of FR4hiCD25hi Treg Cells
To determine then whether the enhancement of alloanti-
gen-specific in vivo and in vitro suppression by
FR4hiCD25hiCD4+ T cells is due to expansion of antigen-
specific Treg cell clones in the FR4hiCD25hi T cell fraction,
we inoculated DBA/2 spleen cells into BALB/c mice and
assessed possible expansion of each FR4-CD25 subpop-
ulation expressing TCR Vb6 subfamily, which specifically
respond to Mls1a antigen (Mtv-7 superantigen) expressed
by DBA/2 spleen cells (Figure 4; Nishimura et al., 2004).
Whereas the percentages of FR4-CD25 subpopulations
among CD4+ T cells did not markedly change 1 week
after immunization, the percentages of FR4hiCD25+ and
FR4hiCD25 cells among Vb6+CD4+ cells increased 2-
fold after DBA/2 stimulation; the percentages of these
populations among Vb6CD4+ T cells did not change
and were similar to those among unstimulated CD4+ T
cells (Figure 4A). The percentages of Vb6+ cells among
more strictly gated FR4-CD25 fractions (fraction a–d in
Figure 4A) similarly changed 1 week after stimulation:
they significantly increased in the FR4hiCD25hi fraction,
decreased in the FR4loCD25 fraction, and greatly
increased in the FR4hiCD25 fraction (Figure 4B). The(D) Amounts of Foxp3 mRNA measured by real-time quantitative PCR before and after stimulation. a–e correspond to the populations shown in (A).
(E) Proliferative responses of T cell subpopulations (a–e in [A]) to restimulation with B6 splenocytes for 5 or 7 days. The means and SDs of triplicates
are shown. Cpm, counts per minute.
(F) Antigen-specific suppressive activity of B6- or C3H-stimulated BALB/c FR4hiCD25hi cells on BALB/c CD25CD4+ T cells at various ratios in 6-day
culture with B6 or C3H splenocytes (APC, antigen-presenting cells).
(G) B6 skin graft survival on BALB/c nude mice after transfer of 23 105 BALB/c naive T cells with 13 105 sorted CD4+ T cell subpopulations shown
in (A).
(H) B6 and C3H skin graft survival in the same BALB/c nude mice after transfer of 2 3 105 BALB/c T cells with 1 3 105 alloantigen-stimulated
FR4hiCD25hi cells. The results in (A)–(F) are representative of more than three independent experiments; those in (G) and (H) are the total of three
separate experiments.Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 149
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increased to a similar extent as among Foxp3 cells, in
contrast with no significant changes in Foxp3+ or Foxp3
cells expressing Mls1a nonreactive TCR Vb10 (Figure 4C).
The results collectively support the hypothesis that
antigen-specific natural Foxp3+ Treg cells in the
FR4hiCD25hi fraction clonally expand after antigen stimu-
lation. In addition, after in vivo antigen stimulation, a great
number of antigen-specific naive T cells, which are
FR4loCD25, differentiate to FR4hiCD25 cells.
Treatment of Tumors by Depleting FR4hi T Cells
Based on the above results indicating high expression of
FR4 as a marker for Foxp3+ natural Treg cells regardless
of whether they are activated or not, we attempted to
control ongoing immune responses by the use of FR4
mAb. In vivo injection of TH6 in a range of 1 to 25 mg
reduced the number of CD25+CD4+ T cells and
CD25CD4+ T cells in the peripheral blood to 20% and
70%, respectively, of control mice and, at a large
amount (100 mg) of injected TH6, to 15% and 50%,
respectively (Figures 5A and 5B). Importantly, injection
of Fab fragment of TH6 also reduced the number of
CD25+CD4+ cells to a similar extent (Figure 5A), indicating
that blockade of FR4 suffices to deplete CD25+CD4+
natural Treg cells.
To examine then whether depletion of FR4-expressing
cells can enhance antitumor immune responses in
tumor-bearing mice, we assessed tumor growth after
TH6 administration to BALB/c mice bearing Meth A fibro-
sarcoma or Colon 26 colorectal adenocarcinoma cells,
both of which are BALB/c derived and neither of which
expressed FR4 (data not shown). The percentages of
FR4hiCD25hi T cells among CD4+ T cells infiltrating into
Meth A tumor masses were higher (2- to 3-fold) than that
in lymph nodes or spleen of the tumor-bearing hosts; the
majority of such FR4hiCD25hiCD4+ T cells were Foxp3+
(Figure 5C). When BALB/c mice were intradermally inocu-
lated with Meth A and i.v. injected with 100 mg of TH6 on
the same day, all the mice rejected tumors and survivedmore than 3 months (Figure 5D). When mice bearing
advanced Meth A or Colon 26 tumors larger than 4 mm
in diameter 8 days after tumor inoculation were treated
3 times with i.v. injection of a small dose (10 mg) of TH6
every 4 days, 60% of the mice rejected tumors and
survived more than 3 months (Figures 5E and 5F). The
majority of control-treated mice died of tumor progression
by 40 days in both experiments.
Next, as an adaptive cell therapy for tumors, lymph
nodes and spleen cells from BALB/c mice with advanced
Meth A tumors were stimulated in vitro with tumor cells
and IL-2 and then transferred to tumor-inoculated BALB/c
nude mice (Figure 6). The stimulated CD4+ T cells
were composed of FR4hiCD25hi, FR4intCD25int-hi, and
FR4loCD25lo cells, whereas CD8+ cells contained FR4int
CD25int-hi and FR4loCD25lo cells, as observed in in vitro
allogeneic stimulation (Figures 2A and 6A). Transfer of
these stimulated CD4+ and CD8+ T cells led to tumor
rejection only in 17% of Meth A-inoculated BALB/c nude
mice. In contrast, when FR4hi cells were removed prior
to cell transfer, a substantially larger number of nude
mice (46%) rejected tumors; they rejected earlier and non-
rejecting mice exhibited retarded tumor growth compared
with those transferred with nondepleted cell suspensions
(Figure 6B).
This transfer of FR4hi cell-depleted T cell suspensions
also induced autoimmune disease in nude mice that had
rejected tumors (Sakaguchi et al., 1995; Shimizu et al.,
1999). Histologically evident autoimmune gastritis (see
below) developed in 20% of them (Figures 6B and 6C).
In contrast, TH6 mAb treatment of tumor-bearing euthy-
mic BALB/c mice hardly elicited autoimmunity (Figures
5D–5F and 6C).
Thus, in vivo depletion of activated Treg cells as FR4hi T
cells can provoke effective tumor immunity even in
advanced stages of tumor progression. Furthermore,
depletion of FR4hi cells from tumor-stimulated T cell
suspensions enhances tumor-killing activity of the cell
suspensions when adoptively transferred to tumor-bear-
ing hosts.Figure 3. In Vivo Antigen-Specific Activation of Treg Cells
(A) Expression of FR4, CD25, and Foxp3 by CD4+ T cells in regional lymph nodes of DO11.10 and Rag2/ DO11.10 mice before and 1 week after
immunization with OVA-CFA. FR4-CD25 expression by Foxp3+ (black dots) and Foxp3 cells (gray dots) after intracellular staining of Foxp3 is shown
(right) with percentages of Foxp3+ cells in each fraction among CD4+ cells.
(B) Expression of Bcl-2 by CD4+ lymph node T cells in DO11.10 mice before and 1 week after OVA immunization. Upper panels show FR4-CD25
expression by Bcl-2lo (black dots) and Bcl-2hi (gray dots) cells. Lower histograms show Bcl-2 expression by Foxp3+ and Foxp3 CD4+ T cells in
DO11.10 mice before and after OVA immunization with percentages of Bcl-2hi cells in Foxp3+ cells.
(C) FR4-CD25 expression by CD4+ T cells in the regional lymph nodes of OVA-CFA-immunized or control BALB/c mice. Numbers indicate the
percentages in each quadrant.
(D) Function of CD4+ T cell subpopulations from BALB/c mice immunized with OVA-CFA 1 week before. Top panel shows the percentages of intra-
cellular Foxp3+ cells in T cell subpopulations (a–d in [C]). Lower 3 panels show proliferation, IL-2 and IFN-g production by T cell subpopulations (a–d in
[C]) after in vitro stimulation with graded concentrations of OVA.
(E) Proliferation and cytokine (IL-2 and IFN-g) production by T cell subpopulations (a–d in [C]) from BALB/c mice immunized with OVA-CFA 3 months
before.
(F) Suppressive activity of OVA-CFA- or CFA-immunized FR4hiCD25hiCD4+ T cells on in vitro proliferation of Rag2/ DO11.10 T cells in the presence
of 300 mg/ml OVA or 0.5 mg/ml CD3 mAb. The open circles represent proliferation of Rag2/ DO11.10 T cells alone. The means and SDs of triplicate
cultures are shown.
(G) Intracellular staining of IL-17 in FR4-CD25 subsets in lymph nodes of 10-month-old SKG mice. IL-17 was stained as previously described (Hirota
et al., 2007). Shown are representative of three independent experiments.Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 151
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Regulatory T Cells Expressing the Folate ReceptorFigure 4. In Vivo Antigen-Specific Expansion of Treg Cells
(A) Expression of FR4, CD25 by CD4+, and TCRVb6+CD4+ lymph node T cells in BALB/cmice immunized with DBA/2 spleen 1 week before. Numbers
show percentages of cells in each quadrant.
(B) Proportion of TCRVb6+ cells in CD4+ T cell subpopulations (a–d in [A]) from BALB/c mice before and 1 week after in vivo stimulation with DBA/2
spleen.
(C) Proportion of TCRVb6+ and TCRVb10+ cells in Foxp3+ and Foxp3 CD4+ T cell subpopulations from BALB/c mice before and 3 days after stim-
ulation with DBA/2 spleen cells. Circles indicate individual mice, and the means and SDs are shown. Student’s t tests were performed for statistical
analyses.Development of Autoimmune Diseases after FR4
mAb Treatment
Although the administration of TH6 to adult BALB/c mice
at a single high dose or several times at a low dose failed
to produce histologically evident autoimmune disease
(Figure 6C), we attempted to determine whether treatment
of youngmice with a large dose of TH6 for a limited period
would elicit autoimmune disease. With administration of
100 mg TH6 mAb to BALB/c mice on day 10 and 20 after
birth, all the mice developed macroscopically evident
gastritis with parietal cell autoantibody (Figures 7A–7C).
Notably, many mice (50%) developed hydronephrosis
(Figures 7D and 7E). They showed histologically evident
inflammatory damage of urinary bladder and ureter,
accompanied by the development of circulating autoanti-
body specific for the epithelial cells of these organs, indi-
cating that the hydronephrosis was due to inflammatory152 Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc.narrowing of the lumen of the organs (Figures 7F–7K).
Similar treatments of young NOD mice, which are geneti-
cally diabetes prone, enhanced the development of diabe-
tes: the treatedmice started to develop the disease before
3months of age and all themice developed overt diabetes
by 5 months of age (Figure 7L) with severe insulitis
(Figure 7M), whereas none of the control NODmice devel-
oped the disease by then and they had only mild insulitis
(Figures 7L and 7N).
In the pancreatic lymph nodes of NOD mice with insuli-
tis, whether they had developed overt diabetes or not,
FR4hiCD25+ cells were Foxp3+ (Figures 7O and 7P and
data not shown). Notably, a discrete population of
FR4loCD25hi cells (about 1% of CD4+ cells) developed in
the pancreatic lymph nodes, but not in the inguinal lymph
nodes, of such NOD mice (fraction a in Figure 7O). The
population was CD45RBlo, CD44hi, CD62Llo, IL-7Rahi,
Immunity
Regulatory T Cells Expressing the Folate ReceptorFigure 5. Induction of Tumor Immunity by FR4 mAb Treatment
(A) Depletion of CD25+CD4+ lymph node T cells 4 days after i.v. injection of 10 mg TH6 or its Fab fragment.
(B) Reduction of CD25+ or CD25CD4+ T cells in peripheral blood lymphocytes (PBLs) 4 days after i.v. injection of graded doses of TH6 or control rat
IgG. The mean and SD of three mice is shown for each dose.
(C) Expression of FR4-CD25 by CD4+ T cells in an inguinal lymph node and the tumor mass from BALB/c mice with Meth A tumor on the back. Num-
bers indicate percentages of CD4+ cells in each quadrant; numbers in blankets indicate percentages of Foxp3+ cells in each fraction.
(D–F) Tumor diameter of each mouse and Kaplan-Mayer survival curve of each group. Meth A-inoculated BALB/c mice were treated with 100 mg TH6
i.v. on day 0 (D). Meth A- or Colon 26-inoculated BALB/c mice ([E] and [F], respectively) were treated with 10 mg TH6 i.v. on day 8, 12, and 16. Arrows
show the days of antibody injection. The results are the total of 3 or 4 separate experiments. Logrank test was performed for statistical analyses.Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 153
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Regulatory T Cells Expressing the Folate ReceptorFigure 6. Adaptive Cell Therapy with Antigen-Stimulated T Cells after Depletion of FR4hi Cells
(A) FR4 and CD25 expression of whole, CD4+, or CD8+ T cells after in vitro stimulation with Meth A cells for 9 days. Right panel shows FR4-CD25
expression of FR4hi-depleted cells.
(B) Stimulated lymphocytes with or without depletion of FR4hi cells were transferred toMeth A-inoculated BALB/c nudemice. Tumor diameter of each
mouse and survival curves of treatedmice are shown. The results are the total of four separate experimentswith Logrank test for statistical estimation.
(C) Autoimmune gastritis in treated mice. Autoantibodies against gastric parietal cells in the sera from FR4mAb-treated BALB/c mice (mice in Figures
5D–5F) or BALB/c nude mice transferred with FR4hi cell-depleted lymphocytes were assessed by ELISA (Sakaguchi et al., 1995). Closed circles rep-
resent macroscopically and histologically evident autoimmune gastritis; open circles represent histologically intact gastric mucosa (Sakaguchi et al.,
1995).IL-2Rb+, Foxp3, and Bcl-2hi (Figure 7P), corresponding
to effector or effector memory T cells (Lanzavecchia and
Sallusto, 2005).
Thus, expression of FR4 and CD25 can separate Treg
cells from effector and memory-like T cells. Treg deletion
by FR4 mAb in young mice can elicit a variety of autoim-
mune diseases depending on the genetic background of
the hosts.
DISCUSSION
We have shown in this report that FR4 is constitutively ex-
pressed in Treg cells at a higher amount compared with154 Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc.other activated or naive T cells before and after antigenic
stimulation. FR4 is not a mere marker for natural Treg cells
but also is functionally essential for their maintenance be-
cause blockade of FR4, for example by administration of
Fab fragment of TH6mAb, was sufficient for reducing nat-
ural Treg cells in vivo. It has been shown that despite in vi-
tro hypoproliferation upon TCR stimulation, natural Treg
cells are more proliferative in vivo than other T cells in
normal naive mice, presumably by responding to self-
antigens or commensal microbes (Fisson et al., 2003;
Setoguchi et al., 2005; Walker et al., 2003). It is therefore
likely that natural Treg cells are highly dependent on folic
acid for their maintenance in the periphery and that high
Immunity
Regulatory T Cells Expressing the Folate Receptorexpression of FR4 may enable them to bind and incorpo-
rate folic acid efficiently. This is similar to the fact that nat-
ural Treg cells are highly dependent on IL-2 for their pe-
ripheral survival, and mere blockade of IL-2 binding can
reduce the number of natural Treg cells (Setoguchi et al.,
2005). Small compounds capable of blocking the uptake
of folic acid or altering its cellular metabolism could selec-
tively control the number of natural Treg cells.
With FR4 as a Treg cell marker, we have shown here that
strong in vivo or in vitro antigenic stimulation activates and
expands not only antigen-specific nonregulatory T cells
but also antigen-reactive Treg cells, leading to an
enhancement of antigen-specific suppression. This en-
hancement of antigen-specific suppressive activity is
mainly due to clonal activation and expansion of anti-
gen-reactive Treg cells, as indicated by the following find-
ings. First, Foxp3-expressingMls1a-reactive BALB/c Vb6+
T cells expanded in the FR4hiCD25hi population after DBA/
2 stimulation whereas Mls1a-nonreactive Foxp3+Vb10+
cells did not. This in vivo expansion of Vb6+ cells corre-
lates with our previous finding that in vitro stimulation of
BALB/c T cells with DBA/2 antigen-presenting cells
resulted in a substantial increase of the number of TCR
Vb6+ T cells in the Foxp3+ Treg population (Nishimura
et al., 2004). Second, not only the number of FR4hiCD25+
T cells but also that of Foxp3+ cells increased 3-fold in the
regional lymph nodes of OVA-CFA-immunized DO11.10
mice compared with nonimmunized mice. Third,
FR4hiCD25+ T cells increased the expression of CTLA-4,
CD69, and CD103 in DO11.10 mice after OVA-CFA immu-
nization. Previous studies by others showed that antigen-
specific Treg cells isolated from TCR transgenic mice ex-
hibited in vivo and in vitro clonal expansion upon antigenic
stimulation (Klein et al., 2003; Tang et al., 2004; Walker
et al., 2003). Also, antigen-pulsed mature DCs were able
to induce proliferation of TCR-transgenic natural Treg
cells in vitro and in vivo (Fehervari and Sakaguchi, 2004;
Yamazaki et al., 2003). Together with these findings, our
results with nontransgenic T cells demarcated by FR4
and CD25 expression indicate that the clonal activation
and expansion of antigen-specific Treg cells physiologi-
cally occurs upon strong antigenic exposure, such as
immunization with protein antigen in CFA or allogeneic
grafts. This may form the cellular basis of antigen-specific
downregulation or tolerance mediated by natural Treg
cells.
The combination of FR4 and CD25 can define two func-
tionally distinct subpopulations of Foxp3 non-Treg CD4+
T cells. FR4hiCD25 cells in BALB/c mice after OVA-CFA
immunization vigorously proliferated and abundantly
produced IL-2 but scarcely produced IFN-g, whereas
FR4loCD25+ cells from the same mice produced a large
amount of IFN-g but showed much less proliferation and
production of IL-2. FR4hiCD25 cells retained this re-
sponse pattern when restimulated in vitro with OVA 3
months after initial immunization. Phenotypically,
FR4loCD25+ cells and FR4hiCD25 cells in antigen-primed
mice were similarly Bcl-2hi, CD44hi, largely CD69hi, largely
CD62Llo, whereas the former were higher in IL-7Ra ex-pression than the latter. Notably, in NOD mice with insuli-
tis, pancreatic lymph nodes but not inguinal lymph nodes
contained a larger number of FR4loCD25hi cells as a phe-
notypically discrete population. Furthermore, FR4loCD25+
cells predominantly secrete proinflammatory cytokines
such as IL-17 and IFN-g. These functional and phenotypic
differences, when taken together, indicate that
FR4loCD25+ cells contain effector and effector memory
T cells, whereas FR4hiCD25 cells, which enormously ex-
pand after antigen stimulation, include central memory T
cells. Distinction between effector memory and central
memory T cells by cell-surface markers has not been clear
in murine CD4+ T cells compared with the human counter-
parts (Lanzavecchia and Sallusto, 2005; Reinhardt et al.,
2001; Sallusto et al., 1999; Seder and Ahmed, 2003;
Sprent and Surh, 2002). The combination of FR4 and
CD25 may help phenotypically distinguishing these T
cell subsets.
Differentiation of activated Treg cells from activated
non-Treg cell effector or memory T cells by FR4 mAb
makes it possible to specifically manipulate Treg cells in
ongoing immune responses. For example, FR4 mAb
(TH6) treatment can preferentially reduce natural Treg
cells, enhance antitumor immune responses, leading to
eradication of even advanced tumors, whereas anti-
CD25 treatment or IL-2 neutralization by IL-2 mAb affects
both Treg cells and effector T cells and therefore may fail
to induce effective tumor immunity against advanced tu-
mors (Ko et al., 2005, and data not shown). Although
high-dose TH6 mAb treatment may reduce FR4hiCD25
memory-like T cells to a certain extent, it apparently
spares FR4loCD25+CD4+ and CD25+CD8+ activated ef-
fector T cells. In addition to such TH6 mAb-mediated
in vivo depletion, in vitro complement-dependent cell lysis
of FR4-expressing cells enhanced antitumor activity of T
cell suspensions from tumor-bearing mice in adoptive im-
munotherapy. In contrast, use of FR4 as a marker for ac-
tivated Treg cells enables us to isolate antigen-activated
and clonally expanded Treg cells as FR4hiCD25hi cells,
for example, from the host undergoing graft rejection, to
expand them ex vivo polyclonally or antigen specifically,
and to transfer them back for suppressing graft rejection.
A similar procedure can also be of use for the treatment of
autoimmune disease by enriching antigen-expanded Treg
cells from the site or regional lymph nodes of autoimmune
tissue damage.
Our study shows the possibility that depletion of FR4-
expressing T cells, especially in young mice, can evoke
severe immune responses to self antigens, in addition to
enhancing immune responses to nonself antigens (such
as allotransplantation antigens) or quasi-self tumor anti-
gens. For example, TH6 mAb treatment of young BALB/
c mice produced not only gastritis, to which BALB/c
mice are genetically susceptible upon depletion or reduc-
tion of Treg cells (Sakaguchi et al., 1995), but also autoim-
mune cystitis, which can be adoptively transferred to
BALB/c nude mice by CD4+ T cells (data not shown).
This autoimmune cystitis can be a good model for human
chronic interstitial cystitis associated with otherImmunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 155
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visto, 1980). In contrast to youngmice, however, TH6mAb
treatment of adult mice at a dose sufficient to provoke ef-
fective tumor immunity failed to elicit histologically evident
autoimmune disease. This indicates that tissue-damaging
autoimmune responses are more tightly regulated than
antitumor immune responses, especially in adult animals.
Nevertheless, the two-sided effect of Treg depletion on tu-
mor immunity and autoimmunity needs to be considered
in its clinical application for immunotherapy of cancer, in
particular in individuals genetically susceptible to autoim-
mune disease.
In conclusion, FR4 is a functionally essential molecule
for Treg cells and also a useful marker for distinguishing
functionally different T cell subpopulations after antigenic
stimulation, in particular between activated Treg cells
and other T cells, and for monitoring immune responses
involving various T cell subpopulations. It needs to be
determined whether FR4 is a useful molecular marker for
manipulating natural Treg cells and other T cell subpopu-
lations in humans as well.
EXPERIMENTAL PROCEDURES
Mice
BALB/c, C57Bl/6 (B6), C3H, DBA/2, and BALB/c nude mice of 6 to 10
weeks of age were purchased from Japan SLC (Shizuoka, Japan), and
NOD mice were purchased from Japan Clea (Tokyo, Japan). RAG2-
deficient DO11.10 TCR transgenic mice were bred in our animal facil-
ity. They were maintained in our animal facility and treated in accor-
dance with the guidelines for animal care in the Institute for Frontier
Medical Sciences, Kyoto University.
Preparation of mAbs
Wistar rats from Charles River Japan (Yokohama, Japan) were three
times i.p. immunized with 5 3 106 cells of CD3 mAb-activated
CD25+CD4+ T cells, and spleen cells were fused with P3U1 myeloma
cells 3 days after the final immunization (Shimizu et al., 2002). Hybrid-
oma cells secreting mAbs that stained CD25+CD4+ T cells in flow
cytometry were selected and cloned. Purified mAbs were conjugated
with biotin (GE Healthcare Bio-Sciences Co., Piscataway, NJ), Alexa
Fluor 455, or FITC (Invitrogen Co., Carlsbad, CA). Fab fragments
were prepared by as previously described (Shimizu et al., 2002).
Immunoprecipitation
Lymph nodes and spleen cells were lysed, incubated with protein G
Sepharose prereacted with antibodies, and subjected to SDS-PAGE
(Shimizu et al., 2002). Protein extracted from bands in SDS-PAGE visu-alized by silver staining (DAIICHI PURE Chemicals, Tokyo, Japan) was
subjected to Mass-Fingerprint analysis (Henzel et al., 1993).
Transfection of FR4 and Foxp3
Cos-7 cells were transfected with the pMXS-IG expression vector
(Kitamura et al., 2003) with or without Folr4 cDNA with Lipofect-
amine2000 (Invitrogen). For the retroviral transduction of Foxp3, CD3
mAb-activated CD25CD4+ T cells were infected with MIGR1 ex-
pressing GFP (Kitamura et al., 2003) with or without Foxp3 cDNA
(Hori et al., 2003).
Flow Cytometry and Cell Sorting
CD4+ T cells were stained with Alexa Fluor 488- or FITC-conjugated
FR4, Phycoerthrin-conjugated CD25 (BD Biosciences, San Jose,
CA), and CyChrome-conjugated CD4 (BD Biosciences) mAbs, and
fractionated to each population by a MoFlo cell sorter (DAKO, A/S,
Denmark) to more than 97% purity of each fraction. For intracellular
Foxp3 staining, cells were fixed after cell-surface staining of FR4,
CD25, and CD4, permeabilized, and stained with Foxp3 mAb (eBio-
science, San Diego, CA).
RT-PCR
Total cellular RNA was extracted with Isogen (Nippon Gene, Tokyo,
Japan) from sorted lymphocytes or mouse placenta. The total amount
of RNA was reverse transcribed with Superscript II reverse-transcrip-
tase and oligo(dT)12-18 primer (Invitrogen). PCR consisted of a dena-
turation step at 94C for 2.5 min, followed by 25–40 cycles (40 cycles
for FR1 and FR2, 30 cycles for FR4, and 25 cycles for HPRT), at 94C
for 30 s, at 60C for 30 s, and at 72C for 45 s, with following primer
sequences: FR1, gggttgtattttacccagtaggagt and aggtaggaaatgtcctta
tgtgctt; FR2, gctggaagactgaactaagacagaa and ggagtcttggatgaagtg
actctta; FR4, cactgtggactgctga and ggctcaaaccacttctg; HPRT, tgaag
agctactgtaatgatcagtcaac and agcaagcttgcaaccttaacca. Real-time
quantitative PCR analysis of Foxp3 was performed as described pre-
viously (Hori et al., 2003).
In Vivo T Cell Activation and In Vitro Assay for
Proliferation and Cytokine Production
For in vivo stimulation, 25 mg of OVA emulsified in 50 ml of CFA was in-
jected into footpads, and 8 days later, popliteal lymph node cells were
collected. Rag2/ DO11.10 T cells (5 3 104 per well) were cultured
with a graded number of FR4hiCD25+CD4+ cells for 5 days in the pres-
ence of 300 mg/ml OVA and 15 Gy-irradiated BALB/c spleen cells (13
105) in U-bottomed 96-well plates; incorporation of 3H-thymidine (1
mCi/well) (Du Pont/NEN, Boston, MA) during the last 6 hr of culture
was measured (Takahashi et al., 1998). In allogeneic mixed lympho-
cytes reactions, CD4+ or CD8+ cells were stimulated with allogeneic
15 Gy-irradiated spleen cells in 1:1 ratio with 50 U/ml IL-2 (Shionogi,
Osaka, Japan) for 3–9 days. In suppression assay, CD25CD4+ cells
(2.5 3 104) were stimulated with irradiated allogeneic spleen cells
(1 3 105) and graded numbers of FR4+CD25+CD4+cells for 5 days,Figure 7. Autoimmune Diseases in Mice Treated with TH6 mAb on Day 10 and 20 after Birth
(A) Autoantibodies against gastric parietal cells in the sera from TH6-treated BALB/c and NOD mice were assessed as in Figure 6C. Closed or open
circles, see Figure 6C.
(B and C) Gastric mucosa from BALB/c mice treated with TH6 (B) or control rat IgG (C). Hematoxilin and eosin (HE) staining (350 as original magni-
fication).
(D and E) Section of a kidney of a BALB/c mouse treated with TH6 (D) or control rat IgG (E). HE staining (31).
(F and G) Bladder of BALB/c mice treated with TH6 (F) or control rat IgG (G). HE staining (350).
(H–K) Indirect immunofluorescence staining of normal bladder (H and J) (350) and ureter (I and K) (3100) with the sera from TH6- or control rat IgG-
treated mice (H) and (I) or control rat IgG (J) and (K). Autoantibody against the epithelia of normal bladder and ureter were detected with Alexa 488-
conjugated anti-mouse IgG antibody as green with counter nuclear staining (POPO-3 iodide) as red.
(L) Incidence of diabetes in NOD mice after treatment with TH6 or control rat IgG.
(M and N) Histology of islets from NOD mice treated with TH6 (M) or control rat IgG (N). HE staining (350).
(O) Expression of FR4 and CD25 by CD4+ T cells in pancreatic or inguinal lymph nodes from NOD mice without overt diabetes.
(P) Pancreatic lymph node CD4+ T cells (gated as shown in [O]) fromNODmice were stained for FR4, CD25, and indicatedmolecules. Foxp3, CTLA-4,
Bcl-2, and Hamster IgG were stained intracellularly. Shown in (O) and (P) are representative of three independent experiments.Immunity 27, 145–159, July 2007 ª2007 Elsevier Inc. 157
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and IFN-g in the culture supernatants were determined by ELISA (eBio-
science).
Tumor Inoculation
BALB/c mice were intradermally inoculated with Meth A (2 3 105) or
Colon 26 cells (1 3 105) and i.v. injected with TH6 mAb (Ko et al.,
2005). Tumor diameter in two directions was measured for each
mouse every 4 days, and mice were sacrificed when the average of
the tumor diameter exceeded 15 mm. For in vitro stimulation with tu-
mor cells, draining lymph nodes and spleen cells from Meth A-bearing
mice were cultured with mitomycin C-treatedMeth A cells and 50 U/ml
IL-2 for 9 days, treated in vitro with TH6 and rabbit complement, and
2 3 106 remaining T cells were i.v. transferred to nude mice that
were inoculated with Meth A cells on the same day.
Histology and Serology
Autoantibodies specific for the gastric parietal cells were determined
by ELISA (Sakaguchi et al., 1995). Urinary or blood glucose levels
weremeasuredwith Testape or theMedisafe reader (TERUMO, Tokyo,
Japan), respectively. Mice with blood glucose levels higher than 300
mg/dl were considered diabetic. Histological and immunohistochem-
ical examination was performed as previously described (Ono et al.,
2006).
Statistical Methods
Logrank or Student’s t test was used for statistical analyses.
Supplemental Data
Six figures are available at http://www.immunity.com/cgi/content/full/
27/1/145/DC1/.
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